RA in Computational Psychiatry & Neuropharmacological Systems @UniofExeter • MSc Clinical Neuroscience @UCL • BSc Psychology @unipotsdam
London, England
Joined July 2023
- Tweets34
- Following396
- Followers48
- Likes156
Lioba Berndt retweeted
Excited to announce the release of our open-source protein family language model, ProFam-1, designed to generate functional protein variants and predict fitness using in-context example sequences. 1/n
Lioba Berndt retweeted
If you're interested in finding out whether these artisanal hand-crafted protein designs actually work: you can vote for my designs to be tested, by giving a ⭐️ here:
proteinbase.com/collections/…
Ok let’s go @adaptyvbio binder design competition: this time designing proteins to neutralise the Nipah virus. Lots of great de novo ML binder design tools out there now, but this year I’m submitting an entry from TEAM HUMAN, seeing if pure rational design can win against the machines.
Lioba Berndt retweeted
Ok let’s go @adaptyvbio binder design competition: this time designing proteins to neutralise the Nipah virus. Lots of great de novo ML binder design tools out there now, but this year I’m submitting an entry from TEAM HUMAN, seeing if pure rational design can win against the machines.
Lioba Berndt retweeted
Article: "Excitation/inhibition imbalance and conversion to psychosis in the clinical high risk syndrome:Biophysical modeling finds reduced pyramidal cell excitability across EEG paradigms"
First Author: @julia_rodsan
medrxiv.org/content/10.1101/…
🧠 Our new paper Restoring Synaptic Balance in Schizophrenia: Insights From a Thalamo-Cortical Conductance-Based Model is now published in Schizophrenia Bulletin.
Our in-silico restoration analysis suggests that coordinated changes across multiple receptor systems - rather than isolated alterations - may help remediate altered neural activity and align it more closely with healthy patterns.
1
2
43
Huge thanks to @DrAlexanderShaw and @magnetokrishio for making this project possible!
1
62
In-silico pharmacological modelling suggests increasing NMDA receptor gain as a potential therapeutic target, implying NMDA receptor hypofunction as a key driver of sleep alterations in these high-risk individuals.
1
1
84
Lioba Berndt retweeted
Article: "A Canonical Microcircuit for Estimating Excitation/Inhibition (E/I) Balance"
Coauthors on X: @HopeOloye, @liobanause
biorxiv.org/content/10.1101/…
Lioba Berndt retweeted
Testing an Active Inference agent in a 3D drone navigation task — it infers its own position and velocity from noisy observations, and selects actions by rolling out belief-based trajectories and minimizing expected free energy.
#ActiveInference #BayesianLearning #AI #AGI
Lioba Berndt retweeted
🚨 New preprint!
"Predictive Coding and Neurocomputational Psychiatry: A Mechanistic Framework for Understanding Mental Disorders"
read it: doi.org/10.31234/osf.io/wd23…
Lioba Berndt retweeted
Some news... This week I passed my PhD viva with no corrections! A big thank you to my examiners @KathaSchmack and @magnetokrishio for such an inspiring discussion, and to my amazing supervisors @dr_rick_adams, @DanHauke and Karl Friston for all their support throughout my PhD!
Lioba Berndt retweeted
New preprint !
"Restoring Synaptic Balance in Schizophrenia: Insights from a thalamo-cortical conductance-based model."
biorxiv.org/content/10.1101/…
with @liobanause and @magnetokrishio.
Lioba Berndt retweeted
Delighted to hear that 5 of my protein designs have been selected for testing! Thanks @adaptyvbio - very excited to see the results
Just submitted some designed proteins to @adaptyvbio EGFR binder competition. My strategy was Chai1 optimization on a diverse set of known EGFR binders shown below. Lower 2 are antibody FABs (necitumumab and panitumumab) which are too large for the competition requirements so...
Lioba Berndt retweeted
Just submitted some designed proteins to @adaptyvbio EGFR binder competition. My strategy was Chai1 optimization on a diverse set of known EGFR binders shown below. Lower 2 are antibody FABs (necitumumab and panitumumab) which are too large for the competition requirements so...